NasdaqCM:SNSS

Stock Analysis Report

Executive Summary

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Share Price & News

How has Sunesis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-13.1%

SNSS

1.7%

US Biotechs

1.3%

US Market


1 Year Return

-69.6%

SNSS

-8.8%

US Biotechs

5.9%

US Market

Return vs Industry: SNSS underperformed the US Biotechs industry which returned -8.8% over the past year.

Return vs Market: SNSS underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

SNSSIndustryMarket
7 Day-13.1%1.7%1.3%
30 Day-39.1%-3.5%-1.9%
90 Day-32.3%-3.1%-1.8%
1 Year-69.6%-69.6%-8.0%-8.8%8.3%5.9%
3 Year-86.2%-86.2%13.9%9.9%45.6%36.2%
5 Year-93.6%-93.6%3.8%-1.2%66.1%47.9%

Price Volatility Vs. Market

How volatile is Sunesis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sunesis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

13.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate SNSS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate SNSS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SNSS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SNSS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SNSS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNSS is overvalued based on its PB Ratio (13.9x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Sunesis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

41.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNSS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNSS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNSS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNSS's revenue (76.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: SNSS's revenue (76.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if SNSS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sunesis Pharmaceuticals performed over the past 5 years?

8.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SNSS is unprofitable, but has reduced losses over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare SNSS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNSS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: SNSS has a negative Return on Equity (-209.58%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SNSS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SNSS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Sunesis Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SNSS's short term assets ($19.8M) exceeds its short term liabilities ($8.7M)

Long Term Liabilities: SNSS's short term assets (19.8M) exceeds its long term liabilities (562.0K)


Debt to Equity History and Analysis

Debt Level: SNSS's debt to equity ratio (46.5%) is considered high

Reducing Debt: SNSS's debt to equity ratio has reduced from 87.8% to 46.5% over the past 5 years.


Balance Sheet

Inventory Level: SNSS has a low level of unsold assets or inventory.

Debt Coverage by Assets: SNSS's debt is covered by short term assets (assets are 3.636730x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNSS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SNSS has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.3% each year.


Next Steps

Dividend

What is Sunesis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SNSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SNSS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SNSS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNSS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNSS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sunesis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Dayton Misfeldt (45yo)

1.8yrs

Tenure

US$574,939

Compensation

Mr. Dayton Misfeldt has been an Interim CEO of Sunesis Pharmaceuticals, Inc. since January 1, 2018 and as its Director since April 2009. Mr. Misfeldt serves as Managing Director and Investment Partner at B ...


Management Age and Tenure

1.8yrs

Average Tenure

48yo

Average Age

Experienced Management: SNSS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

9.1yrs

Average Tenure

66yo

Average Age

Experienced Board: SNSS's board of directors are considered experienced (9.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$1,500,00015 Jul 19
Aisling Capital Management LP
EntityCompany
Shares2,500,000
Max PriceUS$0.60
BuyUS$18,80012 Dec 18
William Quinn
EntityIndividual
Role
Chief Financial Officer
Senior VP of Finance & Corporate Development and CFO
Shares40,000
Max PriceUS$0.47

Ownership Breakdown


Management Team

  • Dayton Misfeldt (45yo)

    Interim CEO & Director

    • Tenure: 1.8yrs
    • Compensation: US$574.94k
  • Dan Swisher (56yo)

    Strategic Advisor

    • Tenure: 1.8yrs
    • Compensation: US$565.45k
  • Debbie Thomas

    Senior Vice President

    • Tenure: 3.7yrs
  • Judy Fox

    Chief Scientific Officer and Executive VP of Research & Development

    • Tenure: 2.8yrs
  • Willie Quinn (48yo)

    Senior VP of Finance & Corporate Development and CFO

    • Tenure: 1.9yrs
    • Compensation: US$501.17k
  • Gene Jamieson

    Vice President of Technical Operations

    • Tenure: 0yrs
  • Par Hyare

    Senior Vice President of Commercial

    • Tenure: 0.3yrs
  • Sean Gharpurey

    Executive Director of Project Management

    • Tenure: 1.3yrs
  • Steve Nava

    Vice President of Quality Assurance

    • Tenure: 1.3yrs

Board Members

  • Dave Stump (69yo)

    Independent Director

    • Tenure: 13.3yrs
    • Compensation: US$92.74k
  • Nicole Onetto (66yo)

    Director

    • Tenure: 0.08yrs
  • Jim Young (74yo)

    Non-Executive Chairman

    • Tenure: 15.8yrs
    • Compensation: US$105.24k
  • Dayton Misfeldt (45yo)

    Interim CEO & Director

    • Tenure: 1.8yrs
    • Compensation: US$574.94k
  • Henry Wolff (70yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$276.08k
  • Steve Ketchum (54yo)

    Independent Director

    • Tenure: 7.7yrs
    • Compensation: US$87.74k
  • Homer Pearce (66yo)

    Independent Director

    • Tenure: 13.3yrs
    • Compensation: US$99.62k
  • Steve Carchedi (57yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$110.24k

Company Information

Sunesis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sunesis Pharmaceuticals, Inc.
  • Ticker: SNSS
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$64.399m
  • Shares outstanding: 111.32m
  • Website: https://www.sunesis.com

Number of Employees


Location

  • Sunesis Pharmaceuticals, Inc.
  • 395 Oyster Point Boulevard
  • Suite 400
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A2ARHWDB (Deutsche Boerse AG)COM PAR USD0.0001 (POST REV SPLT)DEEURNo data
SNSSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2005
RYIPDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2005

Biography

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is v ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 23:57
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.